Viking Global Amends 4DMT Stake, Signals Continued Interest

TL;DR

**Viking Global updated its 4DMT stake, showing continued institutional interest.**

AI Summary

Viking Global Investors LP, a major investment firm, filed an amended SC 13G/A on January 8, 2024, indicating a change in their beneficial ownership of 4D Molecular Therapeutics, Inc. common stock as of December 31, 2023. This update, Amendment No. 3, signals that Viking Global continues to hold a significant stake in the biotech company, which could influence its stock performance and investor confidence. Investors should note that large institutional holdings can provide stability but also pose risks if the institution decides to significantly reduce its position.

Why It Matters

This filing shows that a major institutional investor, Viking Global, is still actively involved with 4D Molecular Therapeutics, which can be a vote of confidence or a signal of potential future changes in their investment strategy.

Risk Assessment

Risk Level: medium — While Viking Global's continued ownership suggests confidence, any future reduction in their stake could negatively impact the stock price.

Analyst Insight

Investors should monitor future SC 13G/A filings from Viking Global Investors LP for any significant changes in their beneficial ownership percentage, as this could signal a shift in their investment thesis for 4D Molecular Therapeutics, Inc.

Key Numbers

• 0001140361-24-001341 — Accession Number (unique identifier for this specific SEC filing)
• 20240108 — Filing Date (the date this SC 13G/A was filed with the SEC)
• 20231231 — Date of Event (the date as of which the ownership change is being reported)
• 35104E100 — CUSIP Number (unique identification number for 4D Molecular Therapeutics, Inc. common stock)
• 005-91921 — SEC File Number (the SEC file number for 4D Molecular Therapeutics, Inc.)

Key Players & Entities

• Viking Global Investors LP (company) — the investment firm filing the SC 13G/A
• 4D Molecular Therapeutics, Inc. (company) — the subject company whose stock is being reported
• DAVID C. OTT (person) — a group member associated with Viking Global
• O. ANDREAS HALVORSEN (person) — a group member associated with Viking Global
• ROSE S. SHABET (person) — a group member associated with Viking Global

Forward-Looking Statements

• Viking Global Investors LP will maintain a significant, but potentially adjusted, stake in 4D Molecular Therapeutics, Inc. throughout 2024. (Viking Global Investors LP) — medium confidence, target: 2024-12-31
• 4D Molecular Therapeutics, Inc. will continue to be a focus for institutional investors interested in biological products. (4D Molecular Therapeutics, Inc.) — medium confidence, target: 2024-12-31

FAQ

Key Financial Figures

• $0.0001 — Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class o

Filing Documents

• ef20018316_sc13ga.htm (SC 13G/A) — 257KB
• 0001140361-24-001341.txt ( ) — 259KB

(a)

Item 1(a). Name of Issuer : 4D Molecular Therapeutics, Inc.

(b)

Item 1(b) . Address of Issuer's Principal Executive Offices : 5858 Horton Street #455, Emeryville, California 94608

(a)

Item 2(a) . Name of Person Filing : Viking Global Investors LP ("VGI"), Viking Global Opportunities Parent GP LLC ("Opportunities Parent"), Viking Global Opportunities GP LLC ("Opportunities GP"), Viking Global Opportunities Portfolio GP LLC ("Opportunities Portfolio GP"), Viking Global Opportunities Illiquid Investments Sub-Master LP ("VGOP"), O. Andreas Halvorsen, David C. Ott and Rose S. Shabet (collectively, the "Reporting Persons")

(b)

Item 2(b) . Address of Principal Business Office or, if none, Residence: The business address of each of the Reporting Persons is: 600 Washington Blvd., Floor 11, Stamford, Connecticut 06901. Item (c) . Citizenship : VGI is a Delaware limited partnership; Opportunities Parent, Opportunities GP and Opportunities Portfolio GP are Delaware limited liability companies; VGOP is a Cayman Islands exempted limited partnership; O. Andreas Halvorsen is a citizen of Norway; and David C. Ott and Rose S. Shabet are citizens of the United States.

(d)

Item 2(d) . Titles of Classes of Securities : Common stock, par value $0.0001 per share ("Common Stock")

(e)

Item 2(e) . CUSIP NUMBER: 35104E100 Item 3 . If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a : (a) Broker or dealer registered under Section 15 of the Exchange Act (b) Bank as defined in Section 3(a)(6) of the Exchange Act (c) Insurance company as defined in Section 3(a)(19) of the Exchange Act (d) Investment company registered under Section 8 of the Investment Company Act of 1940 (e) Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940: see Rule 13d-1(b)(1)(ii)(E) (f) Employee Benefit Plan, Pension Fund which is subject to the provisions of the Employee Retirement Income Security Act of 1974 or Endowment Fund; see Rule 13d-1(b)(1)(ii)(F) (g) Parent holding company, in accordance with Rule 13d-1(b)(1)(ii)(G) CUSIP No. 35104E100 13G Page 11 of 16 Pages (h) Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act. (i) Church Plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940. (j) Non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: (k) Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). Item 4 . The percentages set forth herein are based on 42,753,607 shares of Common Stock outstanding as of November 2, 2023, as reported by the Issuer in its quarterly report on Form 10-Q, filed with the U.S. Securities and Exchange Commission (the "Commission") on November 9, 2023. A. VGI (a) Amount beneficially owned: 4,787,914 (b) Percent of Class: 11.2% (c) Number of shares as to which such person has: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote: 4,787,914 (iii) Sole power to dispose or to direct the disposition of: 0 (i

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct. Dated: January 8, 2024 By: /s/ Scott M. Hendler Name: Scott M. Hendler on behalf of O. Andreas Halvorsen (1) By: /s/ Scott M. Hendler Name: Scott M. Hendler on behalf of David C. Ott (2) By: /s/ Scott M. Hendler Name: Scott M. Hendler on behalf of Rose S. Shabet (3) After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct. (1) Scott M. Hendler is signing on behalf of O. Andreas Halvorsen, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737). (2) Scott M. Hendler is signing on behalf of David C. Ott, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Ott on February 12, 2021 (SEC File No. 005-49737). (3) Scott M. Hendler is signing on

View Full Filing

View this SC 13G/A filing on SEC EDGAR